Olink Holding AB (publ)
OLK
Clasificación en acciones
#4810
Olink Holding AB (publ) offers a comprehensive suite of products and services... Olink Holding AB (publ) offers a comprehensive suite of products and services tailored for life science research institutions, including academic bodies, government entities, biopharmaceutical companies, and biotechnology firms. The company's product lines include Olink Explore, which is designed to aid research in critical areas such as cardiovascular and metabolic health, oncology, neurology, and inflammation. Additionally, it features the Olink Target product line and the Olink Focus product line, the latter providing bespoke solutions for clients who have already pinpointed specific proteins or protein signatures for their studies. Beyond these, Olink supplies the Signature Q100, a dedicated platform for qPCR (quantitative Polymerase Chain Reaction) readouts. Its service portfolio encompasses Olink Analysis, offering end-to-end support from study design and expert consultation to sample preparation, assay execution, and stringent quality control of data, complemented by bioinformatics services. For data management and analysis, Olink provides the normalized protein expression (NPX) Manager, a specialized software tool enabling users to import data, validate its quality, and normalize findings in preparation for statistical analysis. Furthermore, Olink Insight serves as a cloud-based platform for visualizing and statistically analyzing NPX data. Olink Holding AB (publ) markets and sells its offerings worldwide through its proprietary direct sales force, reaching customers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Established in 2004 and based in Uppsala, Sweden, the company underwent a name change in January 2021 from its former identity, Knilo HoldCo AB, to its current designation. It operates as a subsidiary of Summa Equity Holding AB.
Precio por acción
$26.08
Última sincronización: 2024-07-09
Capitalización bursátil
$3.10B
Cambio (1 día)
0.31%
Cambio (1 año)
0.00%
País
SE
Comercio Olink Holding AB (publ) (OLK)
Categoría
Healthcare
Ratio P/E de Olink Holding AB (publ) (OLK)
Ratio P/E al October 2026 TTM: -100.31
Según los últimos informes financieros y el precio de las acciones de Olink Holding AB (publ), el P/E actual (TTM) de la empresa es -100.31. Al final de 2022, la empresa tenía un P/E de -235.17.
Historial del ratio P/E de Olink Holding AB (publ) desde 2019 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | -100.31 | 1.82% |
| 2023 | -98.51 | -58.11% |
| 2022 | -235.17 | 399.08% |
| 2021 | -47.12 | -92.54% |
| 2020 | -631.90 | 163.69% |
| 2019 | -239.64 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 36.15 | -136.04% |
US
|
|
| 39.77 | -139.65% |
US
|
|
| -290.26 | 189.37% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -134.08% |
US
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.